Cutaneous T cell lymphoma atlas reveals malignant T H 2 cells supported by a B cell-rich tumor microenvironment
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Cutaneous T cell lymphoma (CTCL) is a potentially fatal clonal malignancy of T cells primarily affecting the skin. The most common form of CTCL, mycosis fungoides, can be difficult to diagnose, resulting in treatment delay. We performed single-cell and spatial transcriptomics analysis of skin from patients with mycosis fungoides-type CTCL and an integrated comparative analysis with human skin cell atlas datasets from healthy and inflamed skin. We revealed the co-optation of T helper 2 (TH2) cell-immune gene programs by malignant CTCL cells and modeling of the tumor microenvironment to support their survival. We identified MHC-II+ fibroblasts and dendritic cells that can maintain TH2 cell-like tumor cells. CTCL tumor cells are spatially associated with B cells, forming tertiary lymphoid structure-like aggregates. Finally, we validated the enrichment of B cells in CTCL and its association with disease progression across three independent patient cohorts. Our findings provide diagnostic aids, potential biomarkers for disease staging and therapeutic strategies for CTCL.
Description
Funder: This study was funded by the Wellcome Human Cell Atlas Strategic Science Support (WT211276/Z/18/Z). The Wellcome Sanger Institute is supported by core funding from the Wellcome Trust (206194 and 108413/A/15/D).M.H. is funded by Wellcome (WT107931/Z/15/Z) and the NIHR Newcastle Biomedical Research Centre.
Funder: R.L. was funded by the British Heart Foundation
Funder: J.S. is funded by the Clinician Scientist Fellowship of the Austrian Society for Dermatology (OeGDV).
Funder: E.F.M.P. was funded by a Wellcome 4Ward-North Clinical Training Fellowship
Funder: J.N. is supported by a Karolinska Institutet PhD student grant (KID).
Funder: H.B. is funded by the Swedish Society for Medical Research, the Swedish Cancer Foundation, Region Stockholm (clinical research appointment and ALF medicine), Welander and Radiumhemmet foundations.
Funder: N.J.R. is funded by the NIHR Newcastle Biomedical Research Centre, NIHR Newcastle In Vitro Diagnostics Co-operative and NIHR Newcastle Patient Safety Research Collaborative and is a NIHR Senior Investigator
Funder: S.A.T. is funded by the Wellcome Trust (WT206194), the ERC Consolidator grant ThDEFINE (646794), Wellcome Trust (203151/Z/16/Z, 203151/A/16/Z) and the UKRI Medical Research Council (MC_PC_17230).
Keywords
Journal Title
Conference Name
Journal ISSN
1529-2916

